Alzheimer's Therapeutics Targeting Amyloid Beta 1–42 Oligomers II: Sigma-2/PGRMC1 Receptors Mediate Abeta 42 Oligomer Binding and Synaptotoxicity-Reference-Cited by-同舟云学术

Alzheimer's Therapeutics Targeting Amyloid Beta 1–42 Oligomers II: Sigma-2/PGRMC1 Receptors Mediate Abeta 42 Oligomer Binding and Synaptotoxicity

Published:2014-11-12 Issue:11 Volume:9 Page:e111899
ISSN:1932-6203
Container-title:PLoS ONE
language:en
Short-container-title:PLoS ONE

Author:

Izzo Nicholas J.,Xu Jinbin,Zeng Chenbo,Kirk Molly J.,Mozzoni Kelsie,Silky Colleen,Rehak Courtney,Yurko Raymond,Look Gary,Rishton Gilbert,Safferstein Hank,Cruchaga Carlos,Goate Alison,Cahill Michael A.,Arancio Ottavio,Mach Robert H.,Craven Rolf,Head Elizabeth,LeVine Harry,Spires-Jones Tara L.,Catalano Susan M.

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference60 articles.

1. Targeting small Abeta oligomers: the solution to an Alzheimer's disease conundrum;WL Klein;Trends Neurosci,2001

2. Neurotoxicity of Amyloid beta-Protein: Synaptic and Network Dysfunction;L Mucke;Cold Spring Harb Perspect Med,2012

3. Different beta-amyloid oligomer assemblies in Alzheimer brains correlate with age of disease onset and impaired cholinergic activity;F Bao;Neurobiol Aging,2012

4. Detection of a biomarker for Alzheimer's disease from synthetic and clinical samples using a nanoscale optical biosensor;AJ Haes;J Am Chem Soc,2005

5. Soluble fibrillar oligomer levels are elevated in Alzheimer's disease brain and correlate with cognitive dysfunction;JL Tomic;Neurobiol Dis,2009

Cited by 174 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An interim exploratory proteomics biomarker analysis of a phase 2 clinical trial to assess the impact of CT1812 in Alzheimer's disease;Neurobiology of Disease;2024-09

2. CT1812 biomarker signature from a meta‐analysis of CSF proteomic findings from two Phase 2 clinical trials in Alzheimer's disease;Alzheimer's & Dementia;2024-08-21

3. Modeling Alzheimer’s disease using human cell derived brain organoids and 3D models;Frontiers in Neuroscience;2024-08-01

4. Multi-target drugs for Alzheimer's disease;Trends in Pharmacological Sciences;2024-07

5. Neurotoxic β-amyloid oligomers cause mitochondrial dysfunction—the trigger for PANoptosis in neurons;Frontiers in Aging Neuroscience;2024-05-14